Clinical Trial Detail

NCT ID NCT02730130
Title Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.